Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 77


Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.

Franklin JA, Anderson EJ, Wu X, Ambrose CS, Simões EA.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw163.


Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States.

Caspard H, Coelingh KL, Mallory RM, Ambrose CS.

Vaccine. 2016 Sep 30;34(42):5066-72. doi: 10.1016/j.vaccine.2016.08.079. Epub 2016 Sep 6.


SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS.

Am J Perinatol. 2016 May 27. [Epub ahead of print]


Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.

Doucette A, Jiang X, Fryzek J, Coalson J, McLaurin K, Ambrose CS.

PLoS One. 2016 Apr 6;11(4):e0152208. doi: 10.1371/journal.pone.0152208. eCollection 2016.


Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):971-5. doi: 10.1080/21645515.2015.1115936. Epub 2016 Feb 18.


A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.

Caspard H, Heikkinen T, Belshe RB, Ambrose CS.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1721-7. doi: 10.1080/21645515.2015.1115164.


Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.

Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, Talbot HK, Poehling KA, Peters TR, Veney N, Ambrose CS.

Vaccine. 2016 Jan 2;34(1):77-82. doi: 10.1016/j.vaccine.2015.11.010. Epub 2015 Nov 14.


Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States.

La Gamma EF, Kumar VR, Wadhawan R, Ye S, Sifakis F, Ycas J, Ambrose CS.

Am J Perinatol. 2015 Sep;32(11):1017-23. doi: 10.1055/s-0034-1543951. Epub 2015 Apr 15.


The Medicaid Cost of Palivizumab.

Ambrose CS, McLaurin KK.

J Pediatric Infect Dis Soc. 2015 Mar;4(1):83-4. doi: 10.1093/jpids/piu025. Epub 2014 Apr 2. No abstract available.


Standard methods based on last menstrual period dates misclassify and overestimate US preterm births.

Ambrose CS, Caspard H, Rizzo C, Stepka EC, Keenan G.

J Perinatol. 2015 Jun;35(6):411-4. doi: 10.1038/jp.2015.25. Epub 2015 Apr 2.


Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis.

Simões EA, Ambrose CS, Wu X, Anderson EJ.

Pediatr Infect Dis J. 2015 Mar;34(3):331. doi: 10.1097/INF.0000000000000566. No abstract available.


Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.

Hum Vaccin Immunother. 2014;10(10):2789-94. doi: 10.4161/hv.29635.


A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.

Ambrose CS, Chen X, Kumar VR.

Hum Vaccin Immunother. 2014;10(10):2785-8. doi: 10.4161/hv.32082. Epub 2014 Nov 21.


Severe RSV disease in preterm infants born at 29 to 35 weeks' gestation in the United States.

Ambrose CS.

Pediatrics. 2014 Dec;134(6):e1781. doi: 10.1542/peds.2014-2901A. No abstract available.


Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity.

Ambrose CS, Wu X, Caspard H, Belshe RB.

Vaccine. 2014 Sep 29;32(43):5546-8. doi: 10.1016/j.vaccine.2014.07.097. Epub 2014 Aug 12.


The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments.

Makari D, Staat MA, Henrickson KJ, Wu X, Ambrose CS.

Clin Pediatr (Phila). 2015 Jun;54(6):594-7. doi: 10.1177/0009922814546040. Epub 2014 Aug 6. No abstract available.


Seasonal influenza vaccination trends from 2007-2011 in privately insured children and adults in the United States.

Antonova E, Ambrose CS, Kern D, Block SL, Caspard H, Tunceli O.

Vaccine. 2014 Nov 12;32(48):6563-8. doi: 10.1016/j.vaccine.2014.07.009. Epub 2014 Jul 18.



Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL.

Ther Adv Vaccines. 2013 May;1(1):3-5. doi: 10.1177/2051013613486264. No abstract available.


Methods to estimate gestational age can significantly affect study results.

Ambrose CS, Rizzo C, Caspard H.

JAMA Pediatr. 2014 Apr;168(4):388. doi: 10.1001/jamapediatrics.2013.5175. No abstract available.


Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis.

McLaurin K, Ambrose CS.

Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center